To authenticate the advantage of the combined starvation/oxidation therapy and IDO-blockade immunotherapy, the antitumor evaluation was simultaneously performed in vivo in both B16F10 and 4T1 tumor-bearing mouse models. Here, IDO1 is linked to neoplasm.